Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk.
Yu TianYi LinConghui QuVolker ArndtJames W BaurleySonja I BerndtStephanie A BienD Timothy Timothy BishopHermann BrennerDaniel D BuchananArif BudiartoPeter T CampbellRobert Carreras-TorresGraham CaseyAndrew T ChanRui ChenXuechen ChenDavid V ContiVirginia Díez-ObreroNiki DimouDavid A DrewJane C FigueiredoSteven GallingerGraham G GilesStephen B GruberMarc J GunterSophia HarlidTabitha A HarrisonAkihisa HidakaMichael HoffmeisterJeroen R HuygheMark A JenkinsKristina M JordahlAmit D JoshiTemitope O KekuEric KawaguchiAndre E KimAnshul KundajeSusanna C LarssonLoic Le MarchandJuan Pablo LewingerLi LiVictor MorenoJohn MorrisonNeil MurphyHongmei NanRami NassirPolly A NewcombMireia Obón-SantacanaShuji OginoJennifer OseBens PardameanAndrew J PellattAnita R PeoplesElizabeth A PlatzJohn D PotterRoss L PrenticeGad RennertEdward A Ruiz-NarvaezLori C SakodaRobert E SchoenAnna ShcherbinaMariana C SternYu-Ru SuStephen N ThibodeauDuncan C ThomasKonstantinos K TsilidisFranzel J B van DuijnhovenBethany Van GuelpenKala VisvanathanEmily WhiteAlicja WolkMichael O WoodsAnna H WuUlrike PetersW James GaudermanLi HsuJenny Chang-ClaudePublished in: British journal of cancer (2024)
MHT use has a greater impact on the reduction of CRC risk for women at higher genetic risk. These findings have implications for the development of risk prediction models for CRC and potentially for the consideration of genetic information in the risk-benefit assessment of MHT use.